La “FUNDACION ESPAÑOLA PARA LA CURACION DE LA LEUCEMIA MIELOIDE CRONICA”, participa activamente en el avance científico de la curación de la enfermedad, actualmente, la investigación se centra en la búsqueda de otros genes que pueden influir en el desarrollo de la enfermedad.</p align=»justify»>

LISTADO DE PUBLICACIONES MÁS RELEVANTES DEL GELMC (Grupo Español de Leucemia Mieloide Crónica) de los años 2019-2020.

• Año 2022:
• Real‐life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid
• Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra‐deep sequencing of genomic DNA
• Año 2021:

• Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, García-Gutiérrez JV, Conneally E, le Coutre PD, Gattermann N, Martino B, Saussele S, Giles FJ, Ross DM, Aimone P, Li S, Titorenko K, Saglio G. Leukemia. 2021 May;35(5):1344-1355. Epub 2021 Mar 11. PMID: 33707652 PMCID: PMC8102196 DOI: 10.1038/s41375-021-01205-5

• Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Valentín Garcia-Gutiérrez, Alejandro Luna, Juan M. Alonso-Dominguez, Natalia Estrada, Concepcion Boque, Blanca Xicoy, Pilar Giraldo, Anna Angona, Alberto Alvarez-Larrán, Fermin Sanchez-Guijo, María José Ramírez, Elvira Mora, Patricia Vélez, Ana Rosell, Mercedes Colorado Araujo, Beatriz Cuevas, Miguel Sagüés, Montserrat Cortes, Manuel Perez Encinas, Luis Felipe Casado Montero, Melania Moreno Vega, Luis Serrano, Valle Gomez, Carmen Garcia-Hernandez, Sunil Lakhwani, Antonio Paz Coll, Raquel de Paz, Sara Suarez-Varela, Andrés Fernandez-Ruiz, Raul Perez Lopez, Almudena Ortiz-Fernández, Antonio Jiménez-Velasco, Juan Luis Steegmann-Olmedillas, Juan Carlos Hernández-Boluda. Blood Cancer J. 2021 Feb; 11(2): 16. Published online 2021 Feb 9. doi: 10.1038/s41408-021-00420-8 PMID: 33563899

• Año 2020:

• Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia Ruth Stuckey, Juan Francisco López-Rodríguez, Santiago Sánchez-Sosa, Adrián Segura-Díaz, Nuria Sánchez-Farías, Cristina Bilbao-Sieyro, María Teresa Gómez-Casares. World J Clin Oncol. 2020 Dec 24; 11(12): 996–1007. Published online 2020 Dec 24 doi: 10.5306/wjco.v11.i12.996 PMID: 33437662

• Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors Valentín García-Gutiérrez, Juan Carlos Hernández. J Clin Med. 2020 Jul; 9(7): 2251. Published online 2020 Jul 15. doi: 10.3390/jcm9072251 PMID: 32679880

• Año 2019:

• Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety Valentin García-Gutiérrez, Juan Carlos Hernández-Boluda Front Oncol. 2019; 9: 603. Published online 2019 Jul 3. doi: 10.3389/fonc.2019.00603 PMID: 31334123

• Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).Ann Hematol. 2019 Feb; 98(2):321-330. Epub 2018 Nov 16.PMID: 30446802. DOI:10.1007/s00277-018-3507-2
• Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. Colom-Fernández B, Kreutzman A, Marcos-Jiménez A, García-Gutiérrez V, Cuesta-Mateos C, Portero-Sainz I, Pérez-García Y, Casado LF, Sánchez-Guijo F, Martínez-López J, Ayala RM, Boqué C, Xicoy B, Montero I, Soto C, Paz R, Silva G, Vega-Piris L, Steegmann JL, Muñoz-Calleja C. Front Pharmacol. 2019 Nov 25; 10:1340. PMCID: PMC6886582. DOI: 10.3389/fphar.2019.01340. eCollection 2019. PMID:31824308
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Ochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. Leukemia. 2020 Apr; 34(4):966-984. Epub 2020 Mar 3. Review. PMID: 32127639. DOI: 10.1038/s41375-020-0776-2
• Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators (E Abruzzese, L P Akard, A Bosi, F Cervantes, A Charbonnier, F Di Raimondo, G Etienne, V Garcia Gutierrez, A P Guerci-Bresler, H Hjorth-Hansen, J M Karsenti, K R Kelly, P Le Coutre, C Martinez Chamorro, V G Oehler, G Orti Pascual, A Petzer, E Pungolino, G Rege-Cambrin, F Rigal-Huguet, G J Roboz, P Rousselot, F M Sanchez-Guijo, G Sanz Santillana, P Schafhausen, C Scheid, S Schmidt, G Specchia, J L Steegmann, L Stenke). Leukemia. 2020 Jun 22. doi: 10.1038/s41375-020-0915-9. Online ahead of print. PMID: 32572189. DOI: 10.1038/s41375-020-0915-9
• Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes. Stuckey R, Casado LF, Colomer D, Gómez-Casares MT, Casas L, García-Gutierrez V, Sastre JL, Ramírez-Payer Á, Vall-Llovera F, Goñi MÁ, Xicoy B, Godoy AC, Núñez J, Mora I, Vallansot R, López-Lorenzo JL, Palomera L, Conesa V, Noya MS, Sánchez-Guijo F, Peña A, Bautista G, Steegmann JL. J Mol Diagn. 2020 Jul 17:S1525-1578(20)30399-8. PMID: 32688056. DOI: 10.1016/j.jmoldx.2020.06.016
• Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Vigón L, Rodríguez-Mora S, Luna A, Sandonís V, Mateos E, Bautista G, Steegmann JL, Climent N, Plana M, Pérez-Romero P, de Ory F, Alcamí J, García-Gutierrez V, Planelles V, López-Huertas MR, Coiras M. Biochem Pharmacol. 2020 Aug 20;182:114203. PMID: 32828803. DOI: 10.1016/j.bcp.2020.114203DOI: 10.1016/j.jmoldx.2020.06.016